Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies.

Slides:

Advertisements

Similar presentations

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Advertisements

CC-1 Benefit-Risk Assessment Murat Emre, MD Professor of Neurology Istanbul Faculty of Medicine Department of Neurology Behavioral Neurology and Movement.

Interactive Session- Let’s Talk Orthostatic Hypotension

Symptom Control and Enhancing Functioning in Schizophrenia

Preservation of Renal Function: The Key to Long-term Kidney Allograft and Patient Survival.

Familial Chylomicronemia Syndrome

Updates and Perspectives in Diabetic Dyslipidemia

Primary Care Challenges in Depression - To Treat or Refer?

PCSK9 Inhibitors Post-CVOTs

Statin Selection in the Elderly

Improving the Diagnosis and Treatment of Seizures in Long-term Care

What Is Major Depressive Disorder (MDD)?

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

Challenges in the Diagnosis of MS: Physician and Nurse Perspectives

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

This program will include a discussion of off-label treatment and devices and investigational agents and devices not approved by the FDA for use in the.

Does One Size Fit All in Obesity Management?

The Patient Journey to Remission in MDD: A Collaborative Approach

Select Topics in Cardiovascular Medicine

Managing Complex Hypertension: What Every Physician Should Know

New Insights Into Neurogenic Orthostatic Hypotension

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Managing Hard-To-Treat Hypertension: What Every Physician Should Know

Complicated Cases in Ulcerative Colitis

The Mood Disorder Spectrum

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

What Would You Do in This Case of MDD?

Metabolically Healthy Patients With Obesity

The Hypertension in the Very Elderly Trial (HYVET)

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Updates in Pulmonary Arterial Hypertension

Time to Take Gout Seriously

Are We Closer to Personalized Medicine in MS?

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Seizures in the Elderly: Treatment and Special Considerations

Selected Highlights of the Latest Advances in PAH

CoreValve US Pivotal Trial High-Risk Arm Device and Access Routes.

Managing Depression is a Team Effort:

Avoiding Opioid Overuse: Guideline-Based Management of Osteoarthritis

Examining the Latest Evidence in PAH

Novel Approaches in T1D Management

Observational Studies vs. Randomized Controlled Trials (RCT)

Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

ADVANCED PARKINSON'S DISEASE:

Clinical Recognition and Treatment of Levodopa-Induced Dyskinesia

Pseudobulbar Affect or Psychiatric Condition?

Insights Into the Spectrum of Tardive Dyskinesia

Updates in Neurogenic Orthostatic Hypotension

Introduction. Exploring Strategies for Recognition and Management of Lower Limb Spasticity in Children.

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

What's New in Therapeutic Options for Moderate to Severe RA?

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Oral Prostacyclin Pathway Agents in PAH

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Program Goals Background: Anticoagulation in Patients With VTE.

Reducing Risk for CV Outcomes

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

The ABCs of Diagnosing Tardive Dyskinesia

Addressing Cardiovascular Events:

PAH Pathways: What Do the Data Tell Us?”

Binge Eating Disorder.

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Merging the Art and Science of Managing nOH in Clinical Practice

My PAH Patient.

Management of Drug-Induced Movement Disorders: Focus on Tardive Dyskinesia.

TRIAL NAME Presenter NAME Article Reference.

Motor Fluctuations in PD

Translating Data From Trial to Practice

Presentation transcript:

Neurogenic Orthostatic Hypotension: Expert Perspectives on Diagnosis and Treatment Strategies

Neurogenic Orthostatic Hypotension

Non-neurologic Causes of OH

Causes of nOH Impairment of Norepinephrine Release on Standing

Differential Diagnosis

Nocturnal Hypertension Is a Common Problem in nOH Patient Populations

Pronounced BP Variability

Neurotransmitter Disorders

Clinical Parameters

Nonpharmacologic Treatment Options

Pharmacologic Treatment Options

Orthostatic Hypotension Questionnaire (OHQ)

Study 301 Key Inclusion and Exclusion Criteria

Study 301 (cont) OHQ Composite Score After 1 Week

Study 301 (cont) Increase in Standing BP

Study 306B in Patients With PD and nOH Primary Outcome Measure: Dizziness/Lightheadedness

Cardiovascular Disorders in Droxidopa Studies

Falls Related to Droxidopa vs Placebo in Study 306B

Management of Supine Hypertension

Droxidopa vs Levodopa

Benefit-Risk Conclusion for Droxidopa in Patients With nOH

Abbreviations

References

References (cont)